Success Metrics

Clinical Success Rate
71.4%

Based on 5 completed trials

Completion Rate
71%(5/7)
Active Trials
0(0%)
Results Posted
120%(6 trials)
Terminated
2(29%)

Phase Distribution

Ph phase_3
5
71%
Ph phase_4
2
29%

Phase Distribution

0

Early Stage

0

Mid Stage

7

Late Stage

Phase Distribution7 total trials
Phase 3Large-scale testing
5(71.4%)
Phase 4Post-market surveillance
2(28.6%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

71.4%

5 of 7 finished

Non-Completion Rate

28.6%

2 ended early

Currently Active

0

trials recruiting

Total Trials

7

all time

Status Distribution
Completed(5)
Terminated(2)

Detailed Status

Completed5
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
7
Active
0
Success Rate
71.4%
Most Advanced
Phase 4

Trials by Phase

Phase 35 (71.4%)
Phase 42 (28.6%)

Trials by Status

completed571%
terminated229%

Recent Activity

0 active trials
Showing 5 of 7
completedphase_3

Open Label Extension to Bridging Study CTBM100C2303

NCT00982930
completedphase_3

Second Open Label Extension to Bridging Study CTBM100C2303

NCT01069705
terminatedphase_4

Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles

NCT02015663
completedphase_4

Ease of Use and Microbial Contamination of Tobramycin Inhalation Powder (TIP) Versus Nebulised Tobramycin Inhalation Solution (TIS) and Nebulised Colistimethate (COLI)

NCT01844778
completedphase_3

A Study of Tobramycin Inhalation Powder From a Modified Manufacturing Process Versus Placebo

NCT00918957
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT00982930Phase 3

Open Label Extension to Bridging Study CTBM100C2303

Completed
NCT01069705Phase 3

Second Open Label Extension to Bridging Study CTBM100C2303

Completed
NCT02015663Phase 4

Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles

Terminated
NCT01844778Phase 4

Ease of Use and Microbial Contamination of Tobramycin Inhalation Powder (TIP) Versus Nebulised Tobramycin Inhalation Solution (TIS) and Nebulised Colistimethate (COLI)

Completed
NCT00918957Phase 3

A Study of Tobramycin Inhalation Powder From a Modified Manufacturing Process Versus Placebo

Completed
NCT00388505Phase 3

Safety of Tobramycin Inhalation Powder (TIP) vs Tobramycin Solution for Inhalation in Patients With Cystic Fibrosis

Completed
NCT00125346Phase 3

Tobramycin Inhalation Powder (TIP) in Cystic Fibrosis Subjects

Terminated

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7